510(k) device
Pt S Test Strips and Controls for the Coaguchek S System
Roche Diagnostics Corp. · Test, Time, Prothrombin (GJS, Class II) · First FDA decision Oct 24, 2002, newest Oct 24, 2002Anemia, clotting and blood disordersStroke prevention in atrial fibrillation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
9
Naming "Pt S"
MAUDE reports
0
Brand "Pt S", since 2015
PubMed studies
453
Mentioning "Pt S"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Pt S Test Strips and Controls for the Coaguchek S System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K020831 · Decided Oct 24, 2002 · 224 days after receipt
Device type: Test, Time, Prothrombin (GJS) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Home Prothrombin Time/International Normalized Ratio (PT/INR) Monitoring for Anticoagulation ManagementNational determinationOn the books190.11Updated Nov 4, 2026
- Prothrombin Time (PT)National determinationOn the books190.17Updated Oct 1, 2026
- Prothrombin Time (INR) Monitor for Home Anticoagulation ManagementNational analysisReview closedCAG-00087RUpdated Sep 21, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Swelling of Limb)Coding analysisReview closedCAG-00201NUpdated Sep 15, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Pre-operative Examinations)Coding analysisReview closedCAG-00184NUpdated Sep 15, 2026
- Prothrombin Time and Fecal Occult Blood (Revision of ICD-9-CM Codes for Injury to Gastrointestinal Tract)Coding analysisReview closedCAG-00187NUpdated Sep 15, 2026
- Prothrombin Time (PT) NCD 190.17 (Addition of ICD-9-CM diagnosis code 197.7 Secondary Malignant Neoplasm of Liver)Coding analysisReview closedCAG-00404NUpdated Sep 15, 2026
- Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) tests (Removal of Unspecified Joint Replacements)Coding analysisReview closedCAG-00246NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Pt S", any status and sponsor, newest update first.
Kessler FoundationAcademic, hospital or other
NCT07113041 · 45 participants (planned) · Start Jun 1, 2025 · Primary completion Dec 31, 2028
Device: Combined (Robotic balance training and high-definition transcranial direct current stimulation) · For: Stroke; Stroke (CVA) or Transient Ischemic Attack; Stroke Ischemic and 2 more
Sites: West Orange, New Jersey
NECIBE DAMLA ŞAHINAcademic, hospital or other
NCT07276685 · 60 participants · Start Jan 5, 2023 · Primary completion Jul 5, 2025
Device: Low-Level Laser Therapy + Biodentine; Low-Level Laser Therapy + TheraCal PT · For: Primary Tooth Pulpotomy; Vital Pulp Therapy
Sites: Tokat Province, Turkey (Türkiye)
- NEUROBALANCE Training to Improve Postural Control in Individuals With Traumatic Brain InjuryRecruiting
Kessler FoundationAcademic, hospital or other
NCT06584591 · 45 participants (planned) · Start Aug 1, 2025 · Primary completion Aug 2027
Device: Combined (Robotic balance training and high-definition transcranial direct current stimulation) · For: Traumatic Brain Injury; TBI; Diffuse Axonal Brain Injury and 1 more
Sites: West Orange, New Jersey
6 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Pt S", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code GJS
12,207 reports: 11,507 malfunction, 644 injury, 34 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Pt S"[tiab]. The summary above synthesizes these.
- trans-Diamminebis(1,2-di-cyano-ethene-1,2-di-thiol-ato)platinum(IV).
Siddiqui MJ, Nesterov VV, Steidle MT, et al. · IUCrdata · 2020
- Pt-S bond stabilized DNAzyme nanosensor with thiol-resistance enabling high-fidelity biosensing.
Lei Y, He X, Zeng Y, et al. · Talanta · 2024
- Thromboplastin standards.
van den Besselaar AM, Chantarangkul V, Tripodi A · Biologicals · 2010Review
- Restoring Function After TBI: A Review of Physical Therapy Strategies for Balance, Gait, and Dual-Task Recovery.
Vinacco K, Rawnsley N, Kolator E, et al. · R I Med J (2013) · 2025Review
- trans-dichlorobis(di-n-propyl sulfoxide)platinum(II).
Melanson R, Rochon FD · Acta Crystallogr C · 1988Research Support, Non-U.S. Gov't
- Chlorido(dimethyl sulfoxide-κS)[2-(2-pyrid-yl)phenyl-κN,C]platinum(II).
Kobayashi M, Masaoka S, Sakai K · Acta Crystallogr Sect E Struct Rep Online · 2008
- Pt nanozyme-bridged covalent organic framework-aptamer nanoplatform for tumor targeted self-strengthening photocatalytic therapy.
Gao P, Wei R, Chen Y, et al. · Biomaterials · 2023Research Support, Non-U.S. Gov't
- Protruding Pt single-sites on hexagonal ZnIn2S4 to accelerate photocatalytic hydrogen evolution.
Shi X, Dai C, Wang X, et al. · Nat Commun · 2022
- Spatiotemporally Targeted Polypeptide Nanoantidotes Improve Chemotherapy Tolerance of Cisplatin.
Yang J, Su T, Zou H, et al. · Angew Chem Int Ed Engl · 2022Research Support, Non-U.S. Gov't
- beta-Hydrogen Kinetic Effect.
Romeo R, D'Amico G, Sicilia E, et al. · J Am Chem Soc · 2007Research Support, Non-U.S. Gov't
- The in vitro and in vivo depigmenting activity of pterostilbene through induction of autophagy in melanocytes and inhibition of UVA-irradiated α-MSH in keratinocytes via Nrf2-mediated antioxidant pathways.
Hseu YC, Vudhya Gowrisankar Y, Wang LW, et al. · Redox Biol · 2021Research Support, Non-U.S. Gov't
- Phage therapy: A primer for orthopaedic trauma surgeons.
Chen B, Moriarty TF, Metsemakers WJ, et al. · Injury · 2024Review
Other devices of this type
Also filed under product code GJS.
- microINR SystemIline Microsystems, S.L. · 510(k) 2025
- CoaguChek XS Plus SystemRoche Diagnostics · 510(k) 2025
- Coag-Sense Prothrombin (PT) / INR Monitoring System for Patient Self-TestingCoagusense, Inc. · 510(k) 2022
- CoaguChek XS Pro SystemRoche Diagnostics · 510(k) 2018
- Hemosil Recombiplastin 2G (8 Ml Vial)Instrumentation Laboratory CO · 510(k) 2014
- Coaguchek Xs SystemRoche Diagnostics Corp. · 510(k) 2007
- Xprecia Prime Coagulation SystemUniversal Biosensors Pty, Ltd. · 510(k) 2024
- i-STAT PTplus Cartridge with the i-STAT 1 SystemAbbott Laboratories · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.